Patents Assigned to AbbVie Inc.
  • Patent number: 10377540
    Abstract: A container cap configured to couple to an access opening of a container, and the access opening having a seal configured to cover the access opening. The container cap includes a cap body including a cylindrical-shaped side wall having a bottom edge that defines an opening to an interior of the cap body, and a top wall portion integrated with the cylindrical-shaped side wall and at least partially enclosing the interior of the cap body. The container cap further includes a seal opening assembly integrated with the cap body. The seal opening assembly includes a slot defined in the top wall portion of the cap body, and a seal piercing member formed on a first side of the slot. The seal piercing member is configured to pierce the seal covering the access opening.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: August 13, 2019
    Assignee: ABBVIE, INC.
    Inventors: Joy Elizabeth Borgardt, James J. Hughes, Ted Klikuszowian, Todd Marshall, Marc Plew, Kelsey M. Coffey, Scott L. Fisher, Jason A. Rowe
  • Publication number: 20190224220
    Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
    Type: Application
    Filed: April 20, 2017
    Publication date: July 25, 2019
    Applicant: AbbVie Inc.
    Inventors: Philip R. Kym, Eric Voight
  • Publication number: 20190216882
    Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 18, 2019
    Applicant: AbbVie Inc.
    Inventors: Nancy E. Sever, Ulrich Westedt, Ute Lander, Katrin Schneider, Benedikt Steitz, Thomas Mueller, Regina Reul, Constanze Obermiller, Adivaraha Jayasankar, Michael Simon, Yi Gao, Harald Hach, Samuel Kyeremateng, Katharina Asmus, Ping Tong, Donghua Zhu, Marius Naris, Colleen Garrett
  • Patent number: 10344036
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: July 9, 2019
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Ayman Allian
  • Publication number: 20190202812
    Abstract: The present invention features crystalline polymorphs of dimethyl (2S,2?S)-1,1,-((2S,2?S)-2,2,-(4,4,-((2S,5S)-1-(4-tert-butylphenyl) pyrrolidine-2,5-diyl) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,1-diyl)) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-11.
    Type: Application
    Filed: April 25, 2017
    Publication date: July 4, 2019
    Applicant: AbbVie Inc.
    Inventors: Paul J. Brackemeyer, Colleen C. Garrett, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Geoff G. Zhang, Donghua Zhu
  • Patent number: 10329276
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 25, 2019
    Assignee: ABBVIE INC.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Patent number: 10323084
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 18, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • Patent number: 10308610
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 4, 2019
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Patent number: 10300200
    Abstract: A automatic injection device including a housing, a firing mechanism, a near-field communication (NFC) assembly, a syringe, and a plunger. The firing mechanism is disposed within the second end of the housing and includes an activation button moveable relative to the firing body between an initial position and an actuated position. The activation button is configured to deploy the plunger when actuated. The firing mechanism includes a piercing element extending from at least the firing body or the activation button. The NFC assembly includes a film disposed proximate the piercing element and configured to be pierced by the piercing element upon actuation of the activation button. The NFC circuit is configured to indicate a film status including at least an unpierced film status before the film is pierced and a pierced film status after the film is pierced. A method of using the automatic injection device is also disclosed.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 28, 2019
    Assignee: AbbVie Inc.
    Inventors: James J. Hughes, Bhimaprasad Medhal
  • Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20190153108
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • Publication number: 20190154560
    Abstract: Systems and methods for inspecting particles in a liquid beneficial agent are provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Edmund Matayoshi, Shen Tu, Jie Wang
  • Publication number: 20190143034
    Abstract: Device for delivering a beneficial agent to a user includes a cassette including a cassette housing with a fluid reservoir, the cassette housing having a cassette base region, and a delivery tube. The device also includes a pump having a pump housing containing a pump assembly and having a receiving region to receive the cassette base region. The pump assembly includes a fluid drive component, a display, a plurality of input buttons. The pump assembly also includes a first processor coupled to the fluid drive component and the display and configured to reduce power to the fluid drive component and the display when the pump is in an inactive state, and a second processor coupled to the first processor and the plurality of input buttons, the second processor configured to provide an activation signal to the first processor when one or more of the plurality of input buttons is deployed.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 16, 2019
    Applicant: ABBVIE INC.
    Inventors: Phil D. Anderson, Rajkumar Conjeevaram, Ji Zhou, Sean Mackey, Kevin Novak, Ted Hanagan, Mark Panzer, Benjamin Greuel, Jim Hoch, Ryan Thompson
  • Patent number: 10286029
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 14, 2019
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Publication number: 20190134299
    Abstract: A device for delivering a beneficial agent is provided and generally includes a cassette, a pump, and a delivery tube. The pump includes a pump housing containing a pump assembly having a fluid drive component. The pump housing has a receiving region disposed proximate the fluid drive component and further includes a rear closure portion. The rear closure portion includes a membrane disposed between the receiving region and the fluid drive component. The cassette includes a cassette housing, which has a cassette body region defining a fluid reservoir chamber therein. The cassette further includes a cassette base region having a boundary configured to be received by the receiving region.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Applicant: ABBVIE INC.
    Inventors: Phil Anderson, Kevin Novak, Kevin McLennan, Michael Mackaplow, Guiyong Song, Gurjinder Singh Dhami, Benjamin Alan Jasperson, Scott Smieja, Matthew Svacina
  • Patent number: 10280184
    Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 7, 2019
    Assignee: AbbVie Inc.
    Inventors: Michael M. Friedman, Philip Cox, Kristine E. Frank, Michael Z. Hoemann, Augustine Osuma, Noel S. Wilson, Xiangdong Xu, Kevin Cusack, Raymond Huntley, J. Martin Herold
  • Patent number: 10273238
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 30, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel S. Wilson
  • Patent number: 10266532
    Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 23, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Phil B. Cox, Justin D. Dietrich, Kristine E. Frank, Michael M. Friedman, Huan-Qui Li, Kenton L. Longenecker, Augustine T. Osuma, Ann Marie Rowley, Anil Vasudevan, Noel S. Wilson, Jerome Daanen, Stevan Djuric, Amanda W. Dombrowski, Arthur Gomtsyan, Robert Schmidt
  • Patent number: 10269117
    Abstract: Inspection of distribution and morphology of a substance applied to a container includes selectively illuminating at least a portion of a surface of a container using a light source, adjusting the light source to create a resolved view of the substance with sufficient contrast to show a layer of the lubricant disposed on the surface of the container, obtaining an image of the resolved view of the illuminated portion of the surface of the container using an image detector, analyzing image data representing the image of the resolved view, using a data processor, to generate a quantity representing a quality of interaction between the lubricant and the surface of the container, and determining whether the container is acceptable based upon the quantity generated.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: April 23, 2019
    Assignee: ABBVIE INC.
    Inventors: Edmund Matayoshi, Jie Wang, Sheng Tu
  • Patent number: 10238677
    Abstract: The present invention pertains to prevention of and/or treatment for filariasis. In particular, the present invention pertains to the use of tylosin A and its analogs and derivatives to prevent or treat filarial worm infection and/or diseases associated with filarial worm infection. The present invention also pertains to pharmaceutical compositions comprising tylosin A or an analog or derivative thereof for use in preventing or treating filarial worm infection and/or diseases associated with filarial worm infection.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: March 26, 2019
    Assignees: LIVERPOOL SCHOOL OF TROPICAL MEDICINE, ABBVIE INC.
    Inventors: Thomas W. Von Geldern, Dale J. Kempf, Kennan C. Marsh, Mark John Taylor, Stephen Andrew Ward, Louise Ford, Joseph Turner